Compare AEP & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AEP | BDX |
|---|---|---|
| Founded | 1906 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.0B | 51.5B |
| IPO Year | 1999 | 1994 |
| Metric | AEP | BDX |
|---|---|---|
| Price | $132.04 | $165.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 11 |
| Target Price | $132.18 | ★ $189.60 |
| AVG Volume (30 Days) | ★ 3.3M | 2.7M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 2.88% | 2.51% |
| EPS Growth | ★ 19.35 | N/A |
| EPS | ★ 6.66 | 1.34 |
| Revenue | ★ $21,876,000,000.00 | $21,840,000,000.00 |
| Revenue This Year | $6.53 | N/A |
| Revenue Next Year | $4.70 | $2.53 |
| P/E Ratio | ★ $19.82 | $124.92 |
| Revenue Growth | ★ 10.93 | 8.24 |
| 52 Week Low | $98.35 | $162.46 |
| 52 Week High | $134.60 | $231.82 |
| Indicator | AEP | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 64.39 | 27.31 |
| Support Level | $113.08 | N/A |
| Resistance Level | $133.69 | $177.73 |
| Average True Range (ATR) | 2.34 | 4.33 |
| MACD | -0.24 | -1.04 |
| Stochastic Oscillator | 66.99 | 14.67 |
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 42% of AEP's capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (21%), nuclear (8%), and demand response (2%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.